Bio-Reference Laboratories' CEO Discusses Q3 Results - Earnings Call Transcript

Bio-Reference Laboratories Inc (BRLI)

Q3 2012 Earnings Call

August 30, 2012 10:30 am ET

Executives

Delores Bowman - Acting Investor Relations Coordinator

Marc Grodman - President, CEO, Chairman of the Board

Sam Singer - Senior Vice President, CFO

Analysts

Sylvia Chao - William Blair

Dane Leone - Macquarie

Raymond Myers - Benchmark

Mitra Ramgopal - Sidoti

Stephen Shankman - UBS

Presentation

Operator

Good day, ladies and gentlemen and welcome to the Bio-Reference Laboratories Incorporated Third Quarter Fiscal Year 2012 Earnings Conference Call. My name is Aaron, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session toward the end of today's conference. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes.

I will now turn the presentation over to your host for today's conference, Ms. Delores Bowman, Acting Investor Relations Coordinator. Please proceed ma'am.

Delores Bowman

Good morning and welcome to the Bio-Reference Laboratories third quarter 2012 earnings conference call. Bio-Reference Laboratory is one of the largest independent regional full service laboratories in the country with focused marketing capabilities in the areas of genomics, oncology, women's health, correctional health and physician office pathology.

Leading us on the call today will be Dr. Marc Grodman, President and Chief Executive Officer; and Sam Singer, Chief Financial Officer. Some of the commentary made in this presentation may relate to future results and events.

Statements regarding the company's revenue and earnings guidance are based on the company's current expectations. Actual results in future periods may differ materially from those currently expected or desired, because of a number of risks and uncertainties, including general economic and business conditions; future regulatory requirements and mandated pricing reimbursement; the service, customer and geographic market mix of any particular period; the company's ability to effectively manage its operating costs and collect its receivables, the level of demand for the company's products and services and the company's ability to manage its supply and delivery logistics in such an environment.

If you liked this article you might like

Cramer -- Shun Sears, Delta; Nike Beats Under Armour (Unless Curry Finds His Shot)

Cramer: Strong Dollar Means Own Stocks Like UnitedHealth, Humana

Perilous Reversal Stock: Bio-Reference Laboratories (BRLI)

Bio-Reference Labs (BRLI) Stock Gains on Acquisition Despite Earnings Miss

Change at the Top for Two Banks; High Hopes for Cisco